These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 11167946)

  • 21. Unilateral laterothoracic exanthem with coincident evidence of Epstein-Barr virus reactivation: exploration of a possible link.
    Zawar V; Chuh A
    Dermatol Online J; 2008 Jan; 14(1):24. PubMed ID: 18319041
    [No Abstract]   [Full Text] [Related]  

  • 22. Epstein-Barr virus and rheumatoid arthritis.
    Balandraud N; Roudier J; Roudier C
    Autoimmun Rev; 2004 Jul; 3(5):362-7. PubMed ID: 15288002
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Epstein-Barr virus-related plasmablastic lymphomas arising from long-standing sacrococcygeal cysts in immunosuppressed patients.
    Ojanguren J; Collazos J; Martínez C; Alvarez J; Mayo J
    AIDS; 2003 Jul; 17(10):1582-4. PubMed ID: 12824797
    [No Abstract]   [Full Text] [Related]  

  • 24. Epstein-Barr virus and human immunodeficiency virus serological responses and viral burdens in HIV-infected patients treated with HAART.
    O'Sullivan CE; Peng R; Cole KS; Montelaro RC; Sturgeon T; Jenson HB; Ling PD
    J Med Virol; 2002 Jul; 67(3):320-6. PubMed ID: 12116021
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evaluation of Epstein-Barr virus antibodies, anti-VCA avidity by immunofluorescence and immunoblot assays for assessment of Epstein-Barr virus immunologic state.
    Sener AG; Afsar I; Pinar E
    J Virol Methods; 2009 Aug; 159(2):300-2. PubMed ID: 19406156
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phenotype determination of Epstein-Barr virus-infected cells in tissue sections.
    Herbst H; Niedobitek G
    Methods Mol Biol; 2001; 174():93-102. PubMed ID: 11357673
    [No Abstract]   [Full Text] [Related]  

  • 27. Epstein-Barr virus infection is not associated with fibroadenomas of the breast in immunosuppressed patients after organ transplantation.
    Lau SK; Chen YY; Berry GJ; Yousem SA; Weiss LM
    Mod Pathol; 2003 Dec; 16(12):1242-7. PubMed ID: 14681325
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epstein-Barr virus immunossuppression of innate immunity mediated by phagocytes.
    Savard M; Gosselin J
    Virus Res; 2006 Aug; 119(2):134-45. PubMed ID: 16545476
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determination of antigen and fine peptide specificity of EBV-specific CTLs.
    Levitsky V; Frisan T; Masucci M
    Methods Mol Biol; 2001; 174():209-11. PubMed ID: 11357646
    [No Abstract]   [Full Text] [Related]  

  • 30. Rheumatoid arthritis, methotrexate, and lymphoma: risk substitution, or cat and mouse with Epstein-Barr virus?
    Starkebaum G
    J Rheumatol; 2001 Dec; 28(12):2573-5. PubMed ID: 11764198
    [No Abstract]   [Full Text] [Related]  

  • 31. The human T cell immune response to Epstein-Barr virus.
    Landais E; Saulquin X; Houssaint E
    Int J Dev Biol; 2005; 49(2-3):285-92. PubMed ID: 15906243
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A mouse monoclonal antibody against Epstein-Barr virus envelope glycoprotein 350 prevents infection both in vitro and in vivo.
    Haque T; Johannessen I; Dombagoda D; Sengupta C; Burns DM; Bird P; Hale G; Mieli-Vergani G; Crawford DH
    J Infect Dis; 2006 Sep; 194(5):584-7. PubMed ID: 16897655
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of LMP1 in immune control of EBV infection.
    Pai S; Khanna R
    Semin Cancer Biol; 2001 Dec; 11(6):455-60. PubMed ID: 11669607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Screening for Epstein-Barr virus in Hodgkin's lymphoma.
    Khan G
    Methods Mol Biol; 2009; 511():311-22. PubMed ID: 19347303
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Differences between T cell-type and natural killer cell-type chronic active Epstein-Barr virus infection.
    Kimura H; Hoshino Y; Hara S; Sugaya N; Kawada J; Shibata Y; Kojima S; Nagasaka T; Kuzushima K; Morishima T
    J Infect Dis; 2005 Feb; 191(4):531-9. PubMed ID: 15655776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Epstein-Barr virus survival: expression and release of Fas ligand.
    Nagafuchi S
    Intern Med; 2002 Aug; 41(8):603-4. PubMed ID: 12211523
    [No Abstract]   [Full Text] [Related]  

  • 37. [Recombinant AAV-LMP-induced LMP specific cytotoxic response to autologous lymphoblastoid cell lines tranformed by Epstein-Barr virus].
    Zhao F; Liu H; Zhou L; Cai W; Du B; Ye S; Zeng Y
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 1997 Sep; 11(3):247-51. PubMed ID: 15617340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of human herpesvirus 8 and Epstein-Barr virus seropositivity among children in areas endemic and non-endemic for Kaposi's sarcoma.
    Martro E; Bulterys M; Stewart JA; Spira TJ; Cannon MJ; Thacher TD; Bruns R; Pellett PE; Dollard SC
    J Med Virol; 2004 Jan; 72(1):126-31. PubMed ID: 14635020
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The influence of Epstein-Barr virus seropositivity on the efficacy of intravenous immune globulin in children with immune thrombocytopenic purpura.
    Sturgill MG; Drachtman RA; Ettinger AG; Rubin J; Ettinger LJ
    Clin Pediatr (Phila); 1999 Mar; 38(3):171-3. PubMed ID: 10349084
    [No Abstract]   [Full Text] [Related]  

  • 40. [Clinical aspects and diagnosis of Epstein-Barr virus infections].
    Witkowska-Vogtt E
    Przegl Epidemiol; 2002; 56 Suppl 4():25-33. PubMed ID: 14750257
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.